European stock markets traded in the green on Friday, rounding off a broadly negative week dominated by corporate earnings.
Shares of Danish pharmaceutical giant Novo Nordisk slid 4.3% through Friday morning, extending a 2.7% loss on Thursday as analysts pored over the details in its first-quarter results . It puts the stock on track for its sharpest daily decline since August 2022, according to LSEG data. The company reported booming sales for its injectable weight loss treatment Wegovy, which it said had offset a slight reduction in prices.
line Novo Nordisk share price. — Jenni Reid
STOXX 600 Novo Nordisk A/S United States Jerome Powell Prices Novo Nordisk A/S Shell PLC Shell PLC ING Groep NV ING Groep NV Pandora A/S Pandora A/S Societe Generale SA Credit Agricole SA USD/JPY Turkey Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk executive responds to criticisms of Ozempic cost, availabilityNegelle Morris, Novo Nordisk's senior vice president and head of U.S. cardiometabolic sales, spoke exclusively with ABC News.
Read more »
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortagesNovo Nordisk's Negelle Morris spoke exclusively with ABC News.
Read more »
Novo Nordisk trims price for blockbuster obesity drug as competition heats upNovo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while competition from rival Eli Lilly forced the company to cut prices of the drug, knocking its shares.
Read more »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
Novo Nordisk beats profit estimates as sales of weight loss drug Wegovy more than doubleSales of popular weight loss drug Wegovy more than doubled to 9.38 billion kroner.
Read more »